Scarica l'app Stockscreener
0.4612
3.92%
-0.0188
Dopo l'orario di chiusura:
.46
-0.0012
-0.26%
Xtant Medical Holdings Inc Borsa (XTNT) Ultime notizie
Xtant outlines $95M-$99M 2026 revenue outlook as Companion Spine divestiture and Q-code license revenue roll off - MSN
XTNT Q1 2026 Earnings: EPS Misses Estimates Despite Stock GainCommunity Hot Stocks - Newser
Xtant Medical Holdings Inc. (XTNT) Q1 2026 Earnings: EPS Misses Estimates Amidst Narrow LossSenior Analyst Forecasts - Newser
Xtant Medical Holdings (XTNT) Edges Higher: Testing Key Resistance at $0.50Shared Buy Zones - Newser
Xtant Medical Holdings Holds Near Key Resistance Level After Modest GainCommunity Chart Signals - Newser
Xtant Medical Holdings (XTNT) Gains 2.08% as Stock Approaches Key Resistance at $0.50Profitability Factor - Newser
Xtant Medical Balances New Growth Bets With Near-Term Pain - TipRanks
Xtant Medical launches pre-shaped bone graft product line By Investing.com - Investing.com Nigeria
XTNT SEC FilingsXtant Medical 10-K, 10-Q, 8-K Forms - Stock Titan
Xtant Medical raises FY 2026 revenue guidance to $101M-$105M as it adds HEMOBLAST distribution rights - MSN
Xtant Medical Q1 Earnings Call Highlights - Yahoo Finance
B. Riley Financial | Diversified Financial Services Platform - FinancialContent
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Xtant Medical Holdings’ revenue drops to USD 20.9M in Q1 2026 - Medical Buyer
Xtant Medical Holdings, Inc. (AMEX:XTNT) Q1 2026 Earnings Call Transcript - Insider Monkey
Xtant Medical Holdings, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Xtant Medical Boosts 2026 Outlook Amid Tough Quarter - TipRanks
Xtant Medical Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Xtant Medical Holdings Inc Q1 2026 Earnings: Revenue Misses $20.9 million - technotrenz.com
Xtant Medical Holdings, Inc. 2026 Q1 10-Q Report: Financial Results, Strategic Initiatives, and Key Risk Factors - Minichart
Xtant Medical Q1 2026 Results: Revenue Guidance Raised, Balance Sheet Strengthened, Exclusive HEMOBLAST® Bellows Distribution Secured 12 - Minichart
Xtant Medical Q1 2026 Earnings Call Transcript - MarketBeat
XTNT: Raised 2026 revenue guidance to $101M–$105M amid new product launches and reduced debt - TradingView
Xtant Medical Reports First Quarter 2026 Results and Raises Guidance - HarianBasis.co
Xtant Medical Hldgs Q1 2026 Earnings Call Transcript - Yahoo Finance
Xtant Medical launches Trivium Shaped allograft for surgeries - MSN
Xtant Medical Updates Q1 Results and Raises 2026 Guidance - TipRanks
XTNT: Q1 2026 revenue dropped 37% and net loss reached $3.1M amid asset sales and reimbursement shifts - TradingView
Xtant Medical (XTNT) Q1 2026 revenue drops 37% as divestitures hit sales - Stock Titan
XTNT: Raised 2026 revenue guidance to $101–$105M amid asset sales, new product launches, and debt reduction - TradingView
Xtant Medical (NYSE: XTNT) cuts debt, raises 2026 revenue guidance after Q1 - Stock Titan
Press Release: Xtant Medical Reports First Quarter 2026 Financial Results - Moomoo
MSN Money - MSN
TradingKey - TradingKey
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped - Orthopedics This Week
May 13 before trading: Xtant Medical posts Q1 results, 8:30 ET call - Stock Titan
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026 - Morningstar
Xtant Medical launches pre-shaped bone graft product line - Investing.com UK
1.27%
2.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):